Climb Bio: Promising Pipeline Meets Well-Filled Coffers
Reading Time: 3 minutes
Climb Bio is a clinical-stage biotech company specializing in the development of novel antibody therapies for severe immune and kidney diseases. The company currently generates no revenue from drug sales and primarily funds its research and clinical trials through the capital markets. With liquid assets of approximately $239 million, ongoing operations are fully financed until the second half of 2028, allowing the company to present upcoming study data without immediate financial pressure. In search of dynamic impulses in the US biotech...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
